Skip to content
Menu

Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.

Read at benzinga.com

← All stock news